Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes
Authors' conclusion
The pharmacokinetic/pharmacodynamic properties of icodec suggest its potential to provide basal coverage in a basal-bolus insulin regimen in people with T1D.
Study context
- Population
- Individuals with T1D aged 18–64 years, HbA1c ≤75 mmol/mol [≤ 9%]; insulin aspart as bolus insulincrossover
- Participants
- 66 individuals
- Comparison
- Once-weekly icodec vs once-daily insulin glargine U100
Methodological detailsopen-label, two-period crossover
- Open-label
- Two-period crossover
Primary result
As reported in the abstract
steady state
Icodec reached PK steady state on average within
2-3 weeks
Safety
Level 2 hypoglycaemic episodes (PG <3.0 mmol/L [54 mg/dL])
Duration (mean ± SD) Icodec 33 ± 25 min · Glargine U100 30 ± 18 min
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes. Diabetes Obes Metab. Published 20 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →